

Docket No: CELG-0121

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Zeitlin et al.

Serial No: 09/318,151

Group Art Unit: 1614

Filed: May 25, 1999

Examiner: R. Henley, III

For: PHENIDATE DRUG FORMULATIONS HAVING REDUCED ABUSE POTENTIAL

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Assistant Commissioner for Patents on the date shown below.

On July 19, 2001

Michael P. Straher Reg. No. 38,325

HC 00'55
CH 445.00 CH01 FC:217
20 FC:248

07/23/2001 FPAITERS 00000001 233050 09318151

Assistant Commissioner for Patents
Washington, DC 20231

AMENDMENT

In response to the Office Action dated February 9, 2001, in connection with the above referenced patent application, a petition for a three month extension of time to respond thereto and appropriate payment being enclosed herewith, Applicants respectfully request entry of the following amendments, without prejudice, and reconsideration of the outstanding rejections in light of the following remarks.

In the Claims:

Please cancel claims 1, 2, 3, 7 and 8 without prejudice.

Please amend claims 4, 5 and 6 as indicated below:

24. (Amended) The unit dosage of claim 9 comprising from about 2 to about 20 milligrams of D-threo-methylphenidate.

#9/A
(NE)
JLP
7/20/01

OK
TO
ENTER
A

A'

21

A